ArticleClinical kidney journal2015
Management and prevention of post-transplant malignancies in kidney transplant recipients.
Article in Clinical kidney journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- The effect of zoledronic acid on hip geometry in renal transplant recipients: a double-blind placebo-controlled randomized study.BMC nephrology · 2023Trial
- Female liver transplant recipients are at increased risk of developing cervical cancer: A global multicenter study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Outcomes of tyrosine kinase inhibitor monotherapy for advanced renal cell carcinoma arising in patients with kidney transplantation: comparison with sporadic and end-stage renal disease populations.Clinical and experimental nephrology · 2026Article
- Peritoneal lymphomatosis as a rare entity of post-transplant lymphoproliferative disorder after kidney transplantation: a case report.CEN case reports · 2025Article
- Assessing Risk Factors and Posttransplant Outcomes of Nonadherence Among Kidney Transplant Recipients.Transplantation direct · 2025Article
- A Case of Rapidly Progressing Urothelial Carcinoma Arising After Living Donor Kidney Transplantation Treated with Chemotherapy and Immune Checkpoint Inhibitors.Yonago acta medica · 2025Article
- Acute Allograft Rejection in Kidney Transplant Recipients Treated With Immune Checkpoint Inhibitors: An Educational Case Report.Canadian journal of kidney health and disease · 2024Article
- Incidence of Malignancy and Risk Factors Associated with Kidney Transplant Patients.Galen medical journal · 2024Article
- High Non-Cardiac Death Incidence Should Be a Limitation of Drug-Eluting Stents Implantation? Insights from Recent Randomized Data.Diagnostics (Basel, Switzerland) · 2023Review
- Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.Dermatology and therapy · 2023Article
- Multicenter analysis of immunosuppressive medications on the risk of malignancy following adult solid organ transplantation.Frontiers in oncology · 2023Article
- Challenges and Opportunities in the Supply of Living Kidney Donation in the UK National Health Service: An Economic Perspective.Transplantation · 2022Article
- Infection with high-risk genotypes of human papillomavirus and cervical cytological findings among kidney transplant recipients in Kenya: a single centre experience.African health sciences · 2022Article
- Urothelial carcinoma of the graft kidney with molecular analyses: a rare case report.Diagnostic pathology · 2021Article
- Targeting Premature Renal Aging: from Molecular Mechanisms of Cellular Senescence to Senolytic Trials.Frontiers in pharmacology · 2021Review
- Cytotoxic T Lymphocytes (CTLs) and Kidney Transplantation: An Overview.Methods in molecular biology (Clifton, N.J.) · 2021Review
- Relationship between rabbit anti-thymocyte globulin and development of PTLD and its aggressive form in renal transplant population.Renal failure · 2020Article
- Otorhinolaryngological dysfunctions induced by chronic kidney disease in pre- and post-transplant stages.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2020Review
- Molecular Mechanisms of Premature Aging in Hemodialysis: The Complex Interplay Between Innate and Adaptive Immune Dysfunction.International journal of molecular sciences · 2020Review
- The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The central issue in organ transplantation remains suppression of allograft rejection. Thus, the development of immunosuppressive drugs has been the key to successful allograft function. The increased immunosuppressive efficiency obtained in the last two decades in kidney transplantation dramatically reduced the incidence of acute rejection. However, the inevitable trade-off was an increased rate of post-transplant infections and malignancies. Since the incidence of cancer in immunosuppressed transplant recipients becomes greater over time, and the introduction of new immunosuppressive strategies are expected to extend significantly allograft survival, the problem might grow exponentially in the near future. Thus, cancer is becoming a major cause of morbidity and mortality in patients otherwise successfully treated by organ transplantation. There are at least four distinct areas requiring consideration, which have a potentially serious impact on recipient outcome after transplantation: (i) the risk of transmitting a malignancy to the recipient within the donor organ; (ii) the problems of previously diagnosed and treated malignancy in the recipient; (iii) the prevention of de novo post-transplant malignant diseases and (iv) the management of these complex and often life-threatening clinical problems. In this scenario, the direct and indirect oncogenic potential of immunosuppressive therapy should be always carefully considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.